Document:

Exhibit
4.3

 

Warrant
Certificate

 

PURCHASE
WARRANT FOR ORDINARY SHARES

 

Locafy
LIMITED

 

	Warrant Shares:
  ________	Initial Exercise Date: ______,
  2022
	CUSIP:	 
	ISIN:	 

 

THIS
PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [_____]1 (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Locafy Limited, a company incorporated
under the law of the Commonwealth of Australia (the “Company”), up to ______ Ordinary Shares of the Company (as subject
to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall
be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security
held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered
holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of
the Warrant Agency Agreement, in which case this sentence shall not apply.

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Attribution
Parties” has the meaning set forth in Section 2(e) hereof.

 

“Beneficial
Ownership Limitation” has the meaning set forth in Section 2(e) hereof.

 

 

1
Insert the date that is the [__] year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day,
insert the immediately following Trading Day.

 

    	1

    	 

    

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares
are then listed or quoted on a Trading Market, the bid price per Ordinary Share for such date (or the nearest preceding date) on the
Trading Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of per Ordinary Share for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares
are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported on the Pink Open
Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Ordinary
Share reported, or (d) in all other cases, the fair market value of one Ordinary Share as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee”
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.

 

“Buy-In”
shall have the meaning set forth in Section 2(d)(iv) hereof.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Company”
has the meaning set forth in the introductory paragraph of this Warrant.

 

 “DTC”
has the meaning set forth in the introductory paragraph of this Warrant. 

 

“DWAC”
shall have the meaning set forth in Section 2(d)(i) hereof.

 

“Exchange
Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exercise
Price” shall have the meaning set forth in Section 2(b) hereof.

 

“Fundamental
Transaction” shall have the meaning set forth in Section 3(d) hereof.

 

“Holder”
has the meaning set forth in the introductory paragraph of this Warrant.

 

“Initial
Exercise Date” has the meaning set forth in the introductory paragraph of this Warrant.

 

“Notice
of Exercise” has the meaning set forth in Section 2(a) hereof.

 

    	2

    	 

    

 

“Ordinary
Shares” means ordinary shares of the Company, no par value per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.

 

“Ordinary
Share Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Ordinary Shares, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Registration
Statement” means the registration statement on Form F-1 (File No. 333-262442), as amended, filed by the Company with the Commission
and declared effective by the Commission on March __, 2022.

 

“Securities
Act” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary
Trading Market with respect to the Ordinary Shares as in effect on the date of delivery of the Notice of Exercise.

 

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.

 

“Termination
Date” has the meaning set forth in the introductory paragraph of this Warrant.

 

“Trading
Day” and “Trading Days” means a day or days, respectively, on which Ordinary Shares are traded on a Trading
Market.

 

“Trading
Market” means any of the following markets or exchanges on which Ordinary Shares are listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).

 

“Transfer
Agent” means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 150 Royall
Street, Canton, Massachusetts 02021, and any successor transfer agent appointed by the Company.

 

“Underwriting
Agreement” means the underwriting agreement, dated as of March __, 2022, among the Company and H.C. Wainwright &
Co., LLC as representative of the several underwriters named therein, as amended, modified or supplemented from time to time in accordance
with its terms.

 

    	3

    	 

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed
or quoted on a Trading Market, the daily volume weighted average price per Ordinary Share for such date (or the nearest preceding date)
on the Trading Market on which Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price per Ordinary Share for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares are
not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Ordinary Share so
reported, or (d) in all other cases, the fair market value of one Ordinary Share as determined by an independent appraiser selected in
good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.

 

“Warrant
Agency Agreement” means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.

 

“Warrant
Agent” means collectively, Computershare Inc. and Computershare Trust Company, N.A., with a mailing address of 1462 South
4th Street, Louisville, KY 40202, and any successor warrant agent of the Company.

 

“Warrant
Register” has the meaning set forth in Section 4(c) hereof.

 

 “Warrant”
has the meaning set forth in the introductory paragraph of 
this Warrant and “Warrants” means this Warrant and other purchase warrants for Ordinary Shares issued by the
Company pursuant to the Registration Statement.

 

“Warrant
Shares” has the meaning set forth in the introductory paragraph of this Warrant. 

 

“Warrant
Share Delivery Date” has the meaning set forth in Section 2(d)(i) hereof.

 

    	4

    	 

    

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following
the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the number of shares specified in the applicable
Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares
purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day
of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

Notwithstanding
the foregoing in this Section 2(a), a Holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this
Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect
exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder’s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant
Agency Agreement, in which case this sentence shall not apply.

 

b)
Exercise Price. The exercise price per Ordinary Share under this Warrant shall be US$_____, subject to adjustment as provided
herein (the “Exercise Price”).

 

c)
Cashless Exercise. If at the time of exercise of this Warrant there is no effective registration statement registering, or the
prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may be exercised,
in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)
    =	as
  applicable:

 

		(i)	the
                                            VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
                                            if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof
                                            on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section
                                            2(a) hereof on a Trading Day prior to the opening of “regular trading hours”
                                            (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws)
                                            on such Trading Day,

 

    	5

    	 

    

 

		(ii)	at
                                            the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the
                                            date of the applicable Notice of Exercise or (z) the Bid Price of the Ordinary Shares on
                                            the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s
                                            execution of the applicable Notice of Exercise if such Notice of Exercise is executed during
                                            “regular trading hours” on a Trading Day and is delivered within two (2) hours
                                            thereafter (including until two (2) hours after the close of “regular trading hours”
                                            on a Trading Day) pursuant to Section 2(a) hereof or
		(iii)	the
                                            VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
                                            is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
                                            2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

	 	(B)
  =	the
  Exercise Price of this Warrant, as adjusted hereunder; and

 

	 	(X) =	the number of Warrant Shares
  that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of
  a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).

 

d) Mechanics
of Exercise.

 

		i.	Delivery
                                            of Warrant Shares Upon Exercise. Following delivery of the Notice of Exercise, the
                                            Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
                                            Agent to the Holder by crediting the account of the Holder’s or its designee’s
                                            balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian
                                            system (“DWAC”) if the Company is then a participant in such system and
                                            either (A) there is an effective registration statement under the Securities Act permitting
                                            the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
                                            or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
                                            of a certificate, registered in the Company’s share register in the name of the Holder
                                            or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant
                                            to such exercise to the address specified by the Holder in the Notice of Exercise by the
                                            date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of
                                            the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise
                                            Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement
                                            Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
                                            Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall
                                            be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
                                            with respect to which this Warrant has been exercised, irrespective of the date of delivery
                                            of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
                                            in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading
                                            Days and (ii) the number of Trading Days comprising the Standard Settlement Period following
                                            delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the
                                            Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date,
                                            the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
                                            for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Ordinary
                                            Shares on the date of the applicable Notice of Exercise), $10.00 per Trading Day (increasing
                                            to $20.00 per Trading Day on the third Trading Day after the Warrant Share Delivery Date)
                                            for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are
                                            delivered or Holder rescinds such exercise. The Company agrees to use commercially reasonable
                                            efforts to maintain a transfer agent that is a participant in the FAST program so long as
                                            this Warrant remains outstanding and exercisable. Notwithstanding the foregoing, with respect
                                            to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on
                                            the Initial Exercise Date, which may be delivered at any time after the time of execution
                                            of the Underwriting Agreement, the Company agrees to deliver the Warrant Shares subject to
                                            such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial
                                            Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that
                                            payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is
                                            received by such Warrant Share Delivery Date.

 

    	6

    	 

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date (subject to receipt of the aggregate Exercise Price (other than in the case of a cashless
exercise)), then the Holder will have the right to rescind such exercise.

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Ordinary
Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the Ordinary Shares so purchased exceeds (y) the amount obtained by
multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at
issue by (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of Ordinary Shares that would have been issued had
the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Ordinary Shares
having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Ordinary Shares with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver Ordinary Shares upon exercise of the
Warrant as required pursuant to the terms hereof.

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

    	7

    	 

    

 

vii.
Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),
would beneficially own in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of Ordinary
Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Ordinary Shares issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares
which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or
any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such
calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to
be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether
this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each
case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder shall be deemed to represent
to the Company each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in
this paragraph, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act. For purposes of
this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary
Shares as reflected in (A) the Company’s most recent periodic or annual report filed with or furnished to the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall within
two Trading Days confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number
of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares
was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance
of any Warrants, 9.99%) of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation shall in no event exceed 9.99% of the number of Ordinary
Shares outstanding immediately after giving effect to the issuance of Ordinary Shares upon exercise of this Warrant held by the Holder
and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the sixty-first (61st) day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.

 

    	8

    	 

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding:

 

		(i)	pays
                                            a stock dividend or otherwise makes a distribution or distributions on or with respect to
                                            the Ordinary Shares or any other equity or equity equivalent securities payable in Ordinary
                                            Shares (which, for avoidance of doubt, shall not include any Ordinary Shares issued by the
                                            Company upon exercise of this Warrant),

 

		(ii)	subdivides
                                            outstanding Ordinary Shares into a larger number of shares,

 

		(iii)	combines
                                            (including by way of reverse stock split) outstanding Ordinary Shares into a smaller number
                                            of shares, or

 

		(iv)	issues
                                            by reclassification of Ordinary Shares any shares of capital stock of the Company,

 

then
in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall
become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record
holders of any class of shares of its capital stock (the “Purchase Rights”), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares
are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Ordinary Shares as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of Ordinary Shares by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (each a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of Ordinary Shares acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date as of which a record is taken for such Distribution, or, if no such record is taken,
the date as of which the holders of record of Ordinary Shares are to be determined for the participation in such Distribution; provided,
however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any Ordinary Shares as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation.

 

    	9

    	 

    

 

d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Ordinary Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of Ordinary Shares or any compulsory share exchange pursuant to which Ordinary Shares are effectively converted into
or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding Ordinary Shares (not including any Ordinary Shares held by the other Person or other Persons making or party to,
or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the
right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant),
the number of ordinary shares or shares of common stock, as applicable, of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as
a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s
control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company
or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
portion of this Warrant, that is being offered and paid to the holders of Ordinary Shares in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Ordinary Shares are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided,
further, that if holders of Ordinary Shares are not offered or paid any consideration in such Fundamental Transaction, such holders
will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction)
in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black-Scholes
Option Pricing Model obtained from the “OV” function the Bloomberg Terminal service of Bloomberg, L.P. (“Bloomberg”)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day
volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the
Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share
used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of
any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning
on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable
Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section 3(d), (D) a
remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value shall be made by wire transfer of immediately
available funds (or such other consideration) within five Business Days of the Holder’s election (or, if later, on the date of
consummation of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the
Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under
this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the number of Ordinary Shares acquirable and receivable upon exercise of
this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary
Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with
the same effect as if such Successor Entity had been named as the Company herein.

 

    	10

    	 

    

 

e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall
be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.

 

f)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of Ordinary Shares, (C) the
Company shall authorize the granting to all holders of Ordinary Shares rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with
any reclassification of the Company’s capital stock, any consolidation or merger to which the Company (or any of its Subsidiaries)
is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby Ordinary Shares
are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of record of Ordinary
Shares to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of
which it is expected that holders of record of Ordinary Shares shall be entitled to exchange their Ordinary Shares for securities, cash
or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the
failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously furnish such notice with the Commission
pursuant to a Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date
of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    	11

    	 

    

 

g)
Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and
for any period of time deemed appropriate by the board of directors of the Company.

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at
the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the
form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.

 

    	12

    	 

    

 

b)
New Warrants. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying
the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a
new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants
issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.

 

c)
Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose
(the “Warrant Register”), in the name of the Holder of record hereof from time to time. The Company and the Warrant
Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

a)
No Rights as Shareholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it or its designated agent, if
any, including the posting of a surety bond by the Holder (provided that the posting of any such bond by the Holder shall not be required
under this Section 5(b) in connection with Warrants held in book-entry form through DTC (or another established clearing corporation
performing similar functions), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will
make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.

 

    	13

    	 

    

 

d)
Authorized Shares.

 

The
Company covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares may be listed. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

    	14

    	 

    

 

e)
Governing Law. This Warrant shall be governed by and construed in accordance with the law of the State of New York. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the courts of the State
of New York and of the United States of America, in each case sitting in the City and County of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of such courts for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding
to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party
for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at ___________, Attention: ___________, e-mail address: ___________, or such other
e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books
of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i)
the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior
to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously furnish such notice with the Commission pursuant to a Report on Form 6-K.

 

    	15

    	 

    

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Ordinary Share or as a shareholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

o)
Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued
subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant
Agency Agreement, the provisions of this Warrant shall govern and be controlling with respect to the rights and obligations of the Holders
and the Company; provided that, solely with respect to the rights, duties, obligations, protections, immunities and liabilities of the
Warrant Agent, the Warrant Agency Agreement shall govern and control.

 

********************

  

(Signature
Page Follows)

 

    	16

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
written.

 

	 	LOCAFY
    LIMITED
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	Director
    / Company Secretary

 

    	17

    	 

    

 

NOTICE
OF EXERCISE

 

	To:	LOCAFY
  LIMITED

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

Name
of Authorized Signatory: ___________________________________________________________________

Title
of Authorized Signatory: ____________________________________________________________________

Date:
________________________________________________________________________________________

 

    	 

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	_____________________________________
	 	(Please
    Print)
	Address:	_____________________________________
	 

     

    Phone
    Number:

     

    E-mail
    Address:
	(Please
                                            Print)

     

    ______________________________________

     

    ______________________________________

	Dated:
    _______________ __, ______	 
	Holder’s
    Signature:___________________	 
	Holder’s
    Address:___________________Exhibit
10.1

 

 

Executive
Agreement

 

 

Moboom
Limited (ACN 136 737 767)

Company

 

Gavin Burnett

Executive

 

 

 

    	i

     

    

 

Contents

 

	1.	Interpretation	1
	 	 	 
	2.	Term	3
	 	 	 
	3.	Duties	3
	 	 	 
	4.	Location	4
	 	 	 
	5.	Hours
    and Days of Work	4
	 	 	 
	6.	Reporting
    and Supervision	4
	 	 	 
	7.	Performance
    Review	4
	 	 	 
	8.	Policies	4
	 	 	 
	9.	Exclusive
    Service	4
	 	 	 
	10.	External
    Directorships	5
	 	 	 
	11.	Remuneration	5
	 	 	 
	12.	Superannuation	5
	 	 	 
	13.	Expenses	6
	 	 	 
	14.	Annual
    Leave	6
	 	 	 
	15.	Long
    Service Leave	6
	 	 	 
	16.	Personal
    Leave	6
	 	 	 
	17.	Other
    leave	6
	 	 	 
	18.	Public
    Holidays	6
	 	 	 
	19.	Confidentiality	7
	 	 	 
	20.	Intellectual
    Property	7
	 	 	 
	21.	Suspension	8
	 	 	 
	22.	Termination	8
	 	 	 
	23.	Redundancy	10
	 	 	 
	24.	Resignation
    from Other Offices	10
	 	 	 
	25.	Restraint
    of Trade	11
	 	 	 
	26.	Medical
    Tests	12
	 	 	 
	27.	Insurance	12
	 	 	 
	28.	Compliance	12
	 	 	 
	29.	General	13
	 	 	 
	30.	Warranties	14
	 	 	 
	31.	Acknowledgement	14
	 	 	 
	Schedule 1 - Remuneration	15
	 	 	 
	Schedule 2 -  Duties and Position Description - includes Key Performance Indicators	16

 

    	ii

     

    

 

Executive
Agreement

 

	Date	1
    January 2020
	 	 
	Parties	Moboom
    Limited ACN 136 737 767 of 246A Churchill Road, Subiaco WA 6008 (the Company).
	 	 
	 	Gavin Burnett of 3 Roscommon Road, Floreat WA 6014 (the Executive).

 

Recitals

 

	A.	The
    Executive has been performing the role of Chief Executive Officer / Managing Director of the Company since 23 April 2009 but only as a full time employee since 1 July 2012.
	 	 
	B.	The
    Company and the Executive have agreed to enter into a new employment agreement on the terms and conditions set out in this Agreement.

 

	1.	Interpretation

 

	1.1	Interpretations

 

In
this Agreement, unless the context otherwise requires:

 

	 	(a)	words
    importing the singular number include the plural number and vice versa;
	 	 	 
	 	(b)	words
    importing any gender include every gender;
	 	 	 
	 	(c)	where
    a particular word or a phrase is given a particular meaning in this Agreement, other parts of speech and grammatical forms of that
    word or phrase have corresponding meanings;
	 	 	 
	 	(d)	words
    importing persons include natural persons, partnerships, trusts, associations, and bodies corporate;
	 	 	 
	 	(e)	clause
    or sub-clause headings do not affect the interpretation or construction of this Agreement;
	 	 	 
	 	(f)	references
    to recitals, parts, clauses, or paragraphs by letter or number are references to recitals, parts, clauses, or paragraphs in this
    Agreement; and
	 	 	 
	 	(g)	a
    reference to any statute includes a reference to that statute as amended, modified or replaced and includes orders, ordinances, regulations,
    rules and by-laws under or pursuant to that statute.

 

	1.2	Definitions

 

In
this Agreement:

 

“Agreement”
means this employment agreement signed on 23 December 2019.

 

“Board”
means the Company’s Board of Directors as constituted from time to time.

 

    	1

     

    

 

“Complying
Superannuation Fund” has the meaning given in the Superannuation Guarantee (Administration) Act 1992 (Cth).

 

“Confidential
Information” means any and all information which at any time is in the knowledge, possession or control of:

 

	 	(a)	the
    Company; or
	 	 	 
	 	(b)	any
    subsidiary or employee or agent of the Company,

 

relating
to the business, operations or affairs of the Company, or any subsidiary of the Company, including, but not limited to, information relating
to:

 

	 	(c)	Intellectual
    Property;
	 	 	 
	 	(d)	technical
    details of work undertaken by the Company;
	 	 	 
	 	(e)	details
    of contracts, projects or work being undertaken by or involving the Company;
	 	 	 
	 	(f)	details
    of the Company’s internal management practices and procedures;
	 	 	 
	 	(g)	details
    of the Company’s finances;
	 	 	 
	 	(h)	details
    of products developed by the Company; and
	 	 	 
	 	(i)	details
    of the Company’s marketing strategies, customer information and sales databases, but does not include information which is
    lawfully in the public domain otherwise than as a result of a breach of this Agreement.

 

“Documents”
means software (including source code and object code versions), manuals, drawings, diagrams, graphs, charts, projections, specifications,
estimates, records, accounts, plans, formulae, designs, processes, supplier lists, price lists, customer lists, market research information,
correspondence, letters and papers of every description, including all copies of and extracts from any of the same.

 

“Duties”
means the duties described in clause 3 of this Agreement.

 

“Intellectual
Property” means

 

	 	(a)	the
    various rights and property conferred by statute, common law and equity in and in relation to patents of any kind, inventions, utility
    models, designs, copyright, trademarks, trade names, business names, corporate names, logos and get up, circuit layouts, know-how,
    trade secrets and confidential information and the right to have trade secrets and confidential information kept confidential and
    all other intellectual property rights as defined by Article 2 of the World Intellectual Property Organisation Convention of July
    1967;

 

and
includes

 

	 	(b)	all
    applications for registration, extension, renewal or otherwise in respect of the rights and property referred to in paragraph (a)
    of this definition; and
	 	 	 
	 	(c)	all
    rights of action in respect of the rights or property referred to in paragraph (a) of this definition.

 

“Policies”
means the Company’s policies, guidelines and rules as amended or discontinued from time to time and includes any new policies,
guidelines and rules the Company implements.

 

    	2

     

    

 

“Related
Body Corporate” has the meaning set out in section 50 of the Corporations Act (Cth) 2001.

 

“Remuneration”
means the amount described in Schedule 1.

 

“Salary”
means the amount described as “Salary” in Schedule 1.

 

	2.	Term

 

The
Executive’s employment will continue on an ongoing basis, unless terminated earlier in accordance with clause 22 of this Agreement.

 

	3.	Duties

 

	3.1	At
    all times, the Executive will:

 

	 	(a)	carry
    out the Duties listed in Schedule 2 of this Agreement and any other Duties the Company may, from time to time require;
	 	 	 
	 	(b)	discharge
    any responsibility the Company may allocate to him;
	 	 	 
	 	(c)	devote
    the whole of his time, attention and skill, during normal business hours and at such other times as reasonably necessary, to performing
    the Duties and to discharging all of his allocated responsibilities;
	 	 	 
	 	(d)	perform
    the Duties and discharge the allocated responsibilities, in a diligent, faithful and prudent manner;
	 	 	 
	 	(e)	behave,
    at all times, including outside work time, in a manner that is not inconsistent with:

 

	 	(i)	the
    protection and promotion of the Company’s business and good name;
	 	 	 
	 	(ii)	the
    performance of the Duties; or
	 	 	 
	 	(iii)	discharging
    the allocated responsibilities; and

 

	 	(f)	notify
    the Company of any information directly or indirectly relating to any business opportunity relevant to the Company as soon as practicable
    after becoming aware of such information.

 

	3.2	Without
    limiting the Executive’s Duties, during the employment the Executive must not:

 

	 	(a)	act
    in conflict with the Company’s best interests;
	 	 	 
	 	(b)	on
    discovery, allow a conflict between the Executive’s interests and the interests of the Company to continue; or
	 	 	 
	 	(c)	compete,
    or prepare to compete, with the Company;
	 	 	 
	 	(d)	in
    performing the Duties, accept any financial or other benefit except from the Company;
	 	 	 
	 	(e)	use
    internet, email or voicemail at the Company’s workplace for excessive personal use or to view or distribute offensive or illegal
    material; and
	 	 	 
	 	(f)	unlawfully
    discriminate, bully or sexually harass another person.

 

    	3

     

    

 

	4.	Location

 

The
Executive will be located at the Company’s office at 246A Churchill Avenue, Subiaco WA 6008. The Executive may be required to be
located at any other locations that are agreed to by the parties (except that the Executive’s agreement is not required if a new
location is in the Perth region). The Executive may be required to undertake domestic and international travel from time to time as required
to fulfil his responsibilities.

 

	5.	Hours
    and Days of Work

 

The
Executive’s hours of work are 38 hours per week plus reasonable additional hours that are necessary for the Executive to perform
the Duties and to discharge his allocated responsibilities with the required attention and skill.

 

	6.	Reporting
    and Supervision

 

The
Executive will report to the Board, and be subject to the Board’s direction.

 

	7.	Performance
    Review

 

	 	(a)	The Remuneration Committee will formally review the Executive’s performance each year.
	 	 	 
	 	(b)	The
    Executive’s performance will be measured against the Key Performance Indicators set out in Schedule 2, as updated from time
    to time.
	 	 	 
	 	(c)	The
    Chair shall inform the Executive of any concerns the Company has with his performance or conduct as soon as reasonable
    in the circumstances.

 

	8.	Policies

 

	 	(a)	The
    Company must make available to the Executive all Policies with which the Executive must comply with.
	 	 	 
	 	(b)	The
    Company may establish, amend, replace or delete any Policies at its sole discretion from time to time.
	 	 	 
	 	(c)	The
    Company must ensure that the Executive is informed about any amendments to the Policies or about any new or discontinued Policies.
	 	 	 
	 	(d)	The
    Executive agrees to comply with all Policies except that, if there is any inconsistency between the provisions of this Agreement
    and those Policies, then the provisions of this Agreement will prevail over the Policies to the extent of the inconsistency.
	 	 	 
	 	(e)	The
    parties acknowledge that the Policies do not form part of the Executive’s contract of employment with the Company.

 

	9.	Exclusive
    Service

 

The
Executive must not, without the Board’s prior written consent, in any capacity, either during or outside of work time, be engaged
or concerned or have any other interest for financial advantage that:

 

	 	(a)	competes
    with, conflicts with, or detracts from the business of the Company or the business of a Related Body Corporate; or

 

    	4

     

    

 

	 	(b)	interferes
    with:

 

	 	(i)	the
    proper performance of the Duties; or
	 	 	 
	 	(ii)	the
    proper discharge of the Executive’s allocated responsibilities.

 

	10.	External
    Directorships

 

	 	(a)	Subject
    to clause (b), the Executive warrants that the Executive will not be a board member of any entity other than the Company or a Related
    Body Corporate without written consent of the Board.
	 	 	 
	 	(b)	Where
    directed by the Board, the Executive may be the Company’s nominee on the board of entities other than the Company or a Related
    Body Corporate.
	 	 	 
	 	(c)	Apart
    from discretionary trusts and private superannuation funds, the Executive must not accept a directorship or similar positions with
    any entity other than the Company or a Related Body Corporate, without written consent of the Board.

 

	11.	Remuneration

 

	 	(a)	The
    Company shall pay the Executive the Remuneration set out in Schedule 1.
	 	 	 
	 	(b)	The
    Executive will be paid monthly into an account nominated by the Executive.
	 	 	 
	 	(c)	Subject
    to this Agreement, the Remuneration, benefits and any other entitlements provided or referred to in this Agreement are the entire
    consideration payable to the Executive and are compensation for all time worked to fulfil his obligations under this Agreement regardless
    of the number, distribution and timing of the hours of work.

 

	12.	Superannuation

 

	12.1	Company
    Contributions

 

	 	(a)	The
    Company will make the superannuation contributions described in Schedule 1 on behalf of the Executive and to the Executive’s
    account with a Complying Superannuation Fund. The superannuation contributions form part of the Executive’s total
    Remuneration.
	 	 	 
	 	(b)	As
    at the date of this Agreement, the superannuation contributions described in Schedule 1 are in accordance with the contributions
    required by the Company to avoid a tax penalty or charge, pursuant to the Superannuation Guarantee (Administration) Act 1992 (Cth).
	 	 	 
	 	(c)	The
    Company will increase the amount of superannuation contributions as a component of the Executive’s Remuneration if necessary
    at any time to avoid a tax penalty or charge, pursuant to the Superannuation Guarantee (Administration) Act 1992 (Cth) but
    this obligation does not require the Company to increase the Executive’s total Remuneration.

 

	12.2	Executive
    May Make Contributions

 

The
Executive may from time to time request in writing that the Company deduct a sum of money from the Salary and remit it as the Executive’s
contributions to the trustees of a Complying Superannuation Fund nominated by the Executive to the extent permitted by law.

 

    	5

     

    

 

	13.	Expenses

 

Subject
to the production of documentary evidence sufficient to satisfy the Board of their authenticity and reasonableness, the Company will
reimburse the Executive for all reasonable expenses he incurs in performing the Duties and in discharging his responsibilities including:

 

	 	(a)	travel
    costs including fares, accommodation and meals;
	 	 	 
	 	(b)	mobile
    telephone charges;
	 	 	 
	 	(c)	mobile
    device and laptop;
	 	 	 
	 	(d)	membership
    of relevant professional organisations and associations as approved by the Board;
	 	 	 
	 	(e)	professional
    development or training activities; and
	 	 	 
	 	(f)	any
    other expenses properly incurred provided for in the Policies.

 

	14.	Annual
    Leave

 

The
Executive is entitled to 4 weeks’ paid annual leave per annum in accordance with and subject to the Fair Work Act 2009 (Cth).
If the Executive’s employment is terminated, then the Executive will be entitled to payment for any accumulated unused annual leave.

 

	15.	Long
    Service Leave

 

The
Executive is entitled to long service leave in accordance with and subject to the Long Service Leave Act 1958 (WA).

 

	16.	Personal
    Leave

 

	 	(a)	The
    Executive is entitled to 10 days’ paid personal leave per annum in accordance with and subject to the Fair Work Act 2009
    (Cth). Such personal leave is available if the Executive:

 

	 	(i)	is
    unable to attend work due to illness (sick leave); or
	 	 	 
	 	(ii)	is
    required to provide care or support to an immediate family member or other member of the Executive’s household due to their
    illness or unexpected emergency (carer’s leave).

 

	 	(b)	Unused
    personal leave is not paid out on the termination of employment.

 

	17.	Other
    leave

 

The
Executive is entitled to other forms of leave, including parental leave, compassionate leave, and community services leave, in accordance
with and subject to the Fair Work Act 2009 (Cth) and the Paid Parental Leave Act 2010 (Cth).

 

	18.	Public
    Holidays

 

The
Executive in entitled to Public Holidays in accordance with and subject to the Fair Work Act 2009 (Cth).

 

    	6

     

    

 

	19.	Confidentiality

 

	19.1	The
    Executive’s Acknowledgment

 

The
Executive acknowledges that:

 

	 	(a)	during
    his employment with the Company, the Executive will acquire Confidential Information; and
	 	 	 
	 	(b)	because
    of the importance to the Company of the Confidential Information, the Company wishes to protect the Confidential Information during
    the Executive’s employment and after the termination of the Executive’s employment with the Company; and
	 	 	 
	 	(c)	the
    Confidential Information has been and will be acquired by the Company at the Company’s initiative and expense; and
	 	 	 
	 	(d)	the
    Company has expended and will expend effort and money in establishing and maintaining employee skills and the Confidential Information.

 

	19.2	The
    Executive’s Obligations

 

The
Executive agrees that at all times during and after the termination of his employment, he will:

 

	 	(a)	keep
    the Confidential Information confidential; and
	 	 	 
	 	(b)	not
    use it for any purpose other than for the purpose of discharging his obligations to the Company under this Agreement.

 

	19.3	Confidentiality
    of Terms of Agreement

 

The
Company and the Executive must not disclose any of the provisions of this Agreement except:

 

	 	(a)	to
    comply with any applicable law, or any requirement of any regulatory body (including any relevant stock exchange);
	 	 	 
	 	(b)	to
    the extent necessary for either party to meet their obligations under this Agreement;
	 	 	 
	 	(c)	to
    enforce its rights or to defend any claim or action under this Agreement;
	 	 	 
	 	(d)	to
    a professional adviser, financial adviser, banker, financier or auditor if that person is obliged to keep the information confidential;
    or
	 	 	 
	 	(e)	if
    the information has come into the public domain through no fault of that party.

 

	20.	Intellectual
    Property

 

	 	(a)	The
    Executive acknowledges and agrees that the Company is the exclusive owner of all rights, titles and interests in the Documents created
    by him and all Intellectual Property in anything the Executive creates:
	 	 	 
	 	(b)	within
    the scope of his employment; or
	 	 	 
	 	(c)	using
    the Company’s facilities, resources or Confidential Information, notwithstanding that the creation of such Documents or Intellectual
    Property:

 

	 	(i)	is
    not within the scope of the Duties or functions;

 

    	7

     

    

 

	 	(ii)	is
    done by the Executive in his own time; or
	 	 	 
	 	(iii)	involved
    only partial use of the Company’s facilities, resources or Confidential Information; and

 

	 	(d)	for
    any of the Company’s customers or in relation to any of the Company’s contracts or projects, or for any purpose related
    to the Company’s business notwithstanding that the creation of such Documents or Intellectual Property:

 

	 	(i)	is
    not within the scope of the Duties;
	 	 	 
	 	(ii)	is
    done by the Executive in his own time; and
	 	 	 
	 	(iii)	does
    not involve the use of the Company’s facilities or resources.

 

	 	(e)	The
    Executive will, at the Company’s request, do all things necessary to evidence or convey to the Company, ownership of all Intellectual
    Property relating to anything he creates including, but without limitation to the foregoing, all assistance necessary or desirable
    to assist the Company to obtain registration of any rights in respect of the Intellectual Property. The Company must pay the Executive’s
    reasonable expenses associated with complying with this sub-clause.
	 	 	 
	 	(f)	The
    Executive hereby waives, to the fullest extent permissible by law, all moral rights the Executive may have in any copyright works
    or films made in the course of the Executive’s employment. Pursuant to sections 195AW(4) and 195AWA(4) of the Copyright
    Act 1968 (Cth), the Executive hereby consents and acknowledges that the Company may do all or any acts or omissions (whether
    occurring before or after this consent is given) in relation to all copyright works or films made by him, in the course of his employment.

 

	21.	Suspension

 

The
Company may suspend the Executive with full pay for up to 3 months while it investigates any concerns that it has in relation to his
performance or conduct.

 

	22.	Termination

 

	22.1	Termination
    by the Company

 

Subject
to clauses 22.3, the Company may terminate the Executive’s employment:

 

	 	(a)	Within
    the first 24 months of this Agreement by:

 

	 	(i)	giving
    12 months’ notice in writing; or
	 	 	 
	 	(ii)	giving
    to the Executive 6 months’ notice in writing if, by reason of the illness, injury or incapacity of the Executive:

 

	 	A.	the
    Executive is unable to perform the Duties for a total of 13 weeks in any 52 consecutive weeks; or
	 	 	 
	 	B.	the
    Executive becomes permanently incapable of performing the Duties.

 

	 	(b)	After
    the first 24 months of this Agreement and prior to 48 months of employment by:

 

		(i)	giving
                                            6 months’ notice in writing; or

 

    	8

     

    

 

	 	(ii)	giving
    to the Executive 4 months’ notice in writing if, by reason of the illness, injury or incapacity of the Executive:

 

	 	A.	the
    Executive is unable to perform the Duties for a total of 13 weeks in any 52 consecutive weeks; or
	 	 	 
	 	B.	the
    Executive becomes permanently incapable of performing the Duties.

 

	 	(c)	After
    the first 48 months of this Agreement by:

 

	 	(i)	giving
    3 months’ notice in writing; or
	 	 	 
	 	(ii)	giving
    to the Executive 2 months’ notice in writing if, by reason of the illness, injury or incapacity of the Executive:

 

	 	A.	the
    Executive is unable to perform the Duties for a total of 13 weeks in any 52 consecutive weeks; or
	 	 	 
	 	B.	the
Executive becomes permanently incapable of performing the Duties.

 

	22.2	Termination
    by the Executive

 

The
Executive may terminate his employment by giving:

 

	 	(a)	12
    months’ notice in writing, if within the first 24 months of this Agreement or such shorter period of notice as may be agreed
    in writing by the Company.
	 	 	 
	 	(b)	6
    months’ notice in writing, if after the first 24 months of this agreement and prior to 48 months of employment, or such shorter
    period of notice as may be agreed in writing by the Company.
	 	 	 
	 	(c)	3
    months’ notice in writing, if after the first 48 months of this agreement or such shorter period of notice as may be agreed
    in writing by the Company.

 

	22.3	Company
    may pay in lieu

 

The
Company may satisfy the notice requirements in this clause by:

 

	 	(a)	paying
    the Executive an amount equivalent to the Base Salary which he would have earned for the whole notice period; or
	 	 	 
	 	(b)	giving
    part of the notice in writing, and by paying the Executive an amount equivalent to the Base Salary he would have earned during the
    balance of that notice period.

 

	22.4	Termination
    after notice given

 

After
either the Company or the Executive has given notice in accordance with clause 22.1, 22.2 or 22.3(b), the Company may at any time terminate
the employment by paying the Executive an amount equivalent to the Base Salary which the Executive would have earned during the balance
of the notice period.

 

	22.5	Employment
    during notice

 

If
notice is given to terminate the employment, then the Company may do all or any of the following:

 

		(a)	direct
                                            the Executive not to perform the Duties, or any of them, for part or all of the notice period;

 

    	9

     

    

 

	 	(b)	require
    the Executive to remain away from the Company’s premises; and
	 	 	 
	 	(c)	change
    the title of the Executive.

 

	22.6	Termination
    by the Company without notice

 

The
Company may terminate the employment at any time by the Company giving notice of dismissal with immediate effect to the Executive as
a result of:

 

	 	(a)	misconduct
    of the Executive;
	 	 	 
	 	(b)	wilful
    neglect in the discharge of the Duties or his allocated responsibilities;
	 	 	 
	 	(c)	serious
    or persistent breach of the provisions of this Agreement;
	 	 	 
	 	(d)	the
    Executive being charged with a criminal offence or civil penalty order which in the reasonable opinion of the Board brings the Company
    or a Related Body Corporate into disrepute;
	 	 	 
	 	(e)	the
    Executive becoming bankrupt or insolvent or making an arrangement with his creditors generally; or
	 	 	 
	 	(f)	the
    Executive becoming ineligible to hold office as a director of a company.

 

	22.7	Return
    of Property

 

	 	(a)	Upon
    the termination of the Executive’s employment (howsoever caused), the Executive will deliver immediately to the Company all
    Documents and property containing Confidential Information and Intellectual Property, and all other property belonging to the Company,
    which is in the Executive’s possession or under the Executive’s control.
	 	 	 
	 	(b)	The
    Company may require the Executive to provide a written declaration on oath that the Executive has complied with this sub-clause,
    and the Executive agrees that the Company may withhold any monies owing to the Executive unless and until the Executive complies
    with this request.

 

	22.8	Set-off

 

On
termination of the Executive’s employment, the Company may deduct and retain any money owing by the Executive to the Company, from
any amounts due by the Company to the Executive including for Remuneration or accrued leave entitlements to the extent permitted by law.

 

	22.9	No
    Prejudice to Rights

 

The
termination of the Executive’s employment does not prejudice any rights or remedies already accrued to either party under, or in
respect of, any breach of this Agreement.

 

	23.	Redundancy

 

Should
the Executive’s employment terminate for reasons of redundancy, the Executive will be entitled to redundancy pay in accordance
with the applicable minimum redundancy entitlement contained within the National Employment Standards of the Fair Work Act 2009
(Cth).

 

	24.	Resignation
    from Other Offices

 

	 	(a)	On
    termination of the Executive’s employment (howsoever caused) the Executive will forthwith resign, without claim for compensation,
    from any office (including that of director) that the Executive holds within, or on behalf of, the Company or a Related Body Corporate.

 

    	10

     

    

 

	 	(b)	If
    the Executive fails to resign as required by sub-clause 24(a), he irrevocably authorises the Company to appoint another person in
    the Executive’s name and on the Executive’s behalf to execute all documents and to do all things necessary to give effect
    to those resignations.

 

	25.	Restraint
    of Trade

 

	25.1	Definitions

 

In
this clause:

 

	 	(a)	“Restraint
    Area” means Western Australia;
	 	 	 
	 	(b)	“Restraint
    Period” means 3 months following the termination of the Executive’s employment with the Company (howsoever caused);
    and
	 	 	 
	 	(c)	“Business”
    means the business of the Company.

 

	25.2	Restraint

 

During
the Restraint Period, the Executive must not, in the Restraint Area:

 

	 	(a)	solicit
    or compete for the custom of, or accept business from, any person who was a customer of the Company at any time during the 6 months
    immediately preceding the termination of the Executive’s employment with the Company for a business that is the same or similar
    to the Business of the Company;
	 	 	 
	 	(b)	solicit
    or endeavour to obtain the services of any professional person (either directly or indirectly) who was an employee, consultant or
    contractor of the Company at any time during the 3 months immediately preceding the termination of the Executive’s employment
    with the Company; or
	 	 	 
	 	(c)	engage
    in, be involved in or be associated with, or prepare to engage in, be involved in or be associated with, a business competing with
    the Business of the Company in the capacity of a principal, agent, director, employee, partner, majority shareholder or unit holder,
    joint venturer, trustee, beneficiary, contractor, advisor, consultant or in any other capacity.

 

	25.3	Account

 

The
Company is beneficially entitled to any benefits which the Executive obtains as a result of breaching this clause and must account to
the Company for those benefits.

 

	25.4	Acknowledgement

 

Each
of the covenants and restraints in this clause constitutes an independent covenant and restraint separate in all respects from each of
the other covenants and restraints notwithstanding the manner in which they or any of them are linked together or are grouped grammatically,
and the invalidity of any one or more covenant or restraint shall not invalidate the other covenants or restraints. The Executive acknowledges
that the covenants in respect of restraint of trade contained in this clause are:

 

	 	(a)	reasonable
    as to duration, type of activity and geographical area;

 

    	11

     

    

 

	 	(b)	reasonable
    and necessary to protect the proprietary and commercial interests of the Company;
	 	 	 
	 	(c)	commensurate
    with the consideration the Executive will receive under this agreement; and
	 	 	 
	 	(d)	the
    Company is relying upon this acknowledgement in entering into this Agreement.

 

	25.5	Evidence
    of Compliance

 

The
Company may require the Executive to provide a written declaration by the Executive on oath, or any evidence relevant in the circumstances,
confirming to its satisfaction that he is not in breach of his obligations under this clause.

 

	26.	Medical
    Tests

 

	 	(a)	The
    Company may require the Executive to submit to a medical examination or test by its choice of medical practitioners for the purpose
    of determining if:

 

	 	(i)	the
    conditions of clause Error! Reference source not found. and Error! Reference source not found. are satisfied; or
	 	 	 
	 	(ii)	for
    any other reason relevant to his employment with the Company.

 

	 	(b)	The
    Executive must authorise the examining medical practitioner to provide the Company with a report setting out the results of any examination
    or test, and to answer any questions the Company may put to them in relation to the examination, test or report. Once the medical
    practitioner has been so authorised, the Executive must not revoke or restrict that authority.

 

	27.	Insurance

 

The
Company agrees that the Executive will have the benefit of the Company’s directors’ and officers’ insurance, which
insurance must:

 

	 	(a)	apply
    to the Executive from the commencement of employment and thereafter continuously until the period expiring seven years after termination
    of employment;
	 	 	 
	 	(b)	apply
    to the Executive in connection with the employment;
	 	 	 
	 	(c)	apply
    to the Executive in connection with all positions the Employee holds on the Board; and
	 	 	 
	 	(d)	indemnify
    the Executive against all actual legal costs and all liabilities in connection with claims, demands, liabilities, judgments, orders
    and costs against the Executive.

 

	28.	Compliance

 

	 	(a)	The
    exercise of or compliance with any discretion, right or obligation pursuant to this Agreement are subject to:

 

	 	(i)	compliance
    with all applicable laws;
	 	 	 
	 	(ii)	compliance
    with the Constitution of the Company and, if applicable, the Listing Rules of the Australian Stock Exchange; and
	 	 	 
	 	(iii)	the
    approval of the shareholders of the Company where such approval is required.

 

    	12

     

    

 

	 	(b)	If
    approval of the shareholders of the Company is required before a payment may be made to the Executive, then the Company must ensure
    that the approval of the shareholders is sought unless the Executive agrees otherwise.
	 	 	 
	 	(c)	If
    the aggregate of any amounts payable pursuant to this Agreement that are subject to section 200B of the Corporations Act 2001
    (Cth) (Termination Benefit) would, at the time for payment, exceed the amount that is permitted pursuant to any applicable
    exemption from section 200B and shareholder approval is not obtained, then the Termination Benefit will be reduced to the greatest
    amount that may then be payable without shareholder approval and that reduced amount must be paid by the Company to the Executive.

 

	29.	General

 

	29.1	Survival
    of Terms

 

Any
provisions of this Agreement which are expressed to operate after the termination of this Agreement will survive the termination of this
Agreement (howsoever caused) and shall be without prejudice to any right of action already accrued to either party in respect of any
breach of this Agreement by the other party.

 

	29.2	Proper
    Law and Jurisdiction

 

This
Agreement is governed by and interpreted in accordance with the laws of the state of Western Australia and the Commonwealth of Australia
and the parties submit to the exclusive jurisdiction of the courts of Western Australia and the Commonwealth of Australia.

 

	29.3	Prior
    Agreements

 

This
Agreement constitutes the entire agreement between the parties and supersedes and cancels all prior representations, warranties, agreements,
contractual terms, covenants and guarantees.

 

	29.4	Release
    from prior arrangements

 

The
parties each release the other from all proceedings, claims, demands, costs and other liabilities of any nature in connection with the
contractual arrangements applying between them prior to this Agreement.

 

	29.5	Waiver

 

No
waiver of any breach of any term of this Agreement will be effective unless that waiver is in writing, and no waiver of any breach will
be, or be deemed to be, a waiver of any other or subsequent breach.

 

	29.6	Severance

 

If
any terms or conditions of this Agreement are void, or become voidable or unenforceable, by reason of any statute or rule of law, then
that term or condition shall be severed from this Agreement without affecting the enforceability of the remaining terms and conditions.

 

	29.7	Variation

 

Except
as provided in this Agreement, this Agreement may only be varied by agreement in writing.

 

    	13

     

    

 

	30.	Warranties

 

	30.1	Warranties
    by the Executive

 

The
Executive warrants:

 

	 	(a)	that
    the Executive has disclosed to the Company all information about any possible restrictions on the Executive from performing the Duties;
	 	 	 
	 	(b)	other
    than what the Executive has disclosed to the Company, that the Executive is not restricted from performing the Duties in connection
    with a restrictive covenant or other non-competition obligation owed to anyone, or a restriction imposed on the Executive concerning
    the use of any information or the intellectual property rights of anyone;
	 	 	 
	 	(c)	that
    the credentials and information provided by the Executive to the Company (or to the Company’s agent) in connection with the
    Executive’s qualifications and ability to perform the duties pursuant to this Agreement are true and correct; and
	 	 	 
	 	(d)	other
    than what the Executive has disclosed to the Company, that prior to accepting employment, the Executive has not suffered from an
    occupational disease in any trade, industry or process.

 

	30.2	Warranties
    by Company

 

The
Company warrants that other than as disclosed in this Agreement:

 

	 	(a)	it
    has obtained all approvals, including all necessary Board approvals required pursuant to this Agreement; and
	 	 	 
	 	(b)	no
    obligations interfere with the Company’s ability to enter into this Agreement.

 

	31.	Acknowledgement

 

The
Executive acknowledges that he has read and understands the conditions of employment detailed in this Agreement and accepts employment
with the Company on those terms.

 

    	14

     

    

 

Schedule
1 – Remuneration

 

	FIXED REMUNERATION:	 	$	328,500
                                            per annum	 
	Made up as:	 	 	 	 
	Base Salary:	 	$	300,000
                                       per annum	 
	Superannuation:

	 	$	28,500
                                            per annum
 (at
                                            9.5% of base salary)
	 

 

SHORT
TERM INCENTIVE PLAN

 

FY2021

 

	%
    Gross Revenue Target	 	 	$
    Gross Revenue Target	 	 	%
    Increase to Base Salary (New Base Salary)	 	 	Cash
    Bonus 
(% of New Base Salary)	 
	 	100	%	 	$	5,000,000	 	 	 	25	%	 	 	0	%
	 	105	%	 	$	5,250,000	 	 	 	25	%	 	 	0	%
	 	110	%	 	$	5,500,000	 	 	 	25	%	 	 	0	%
	 	115	%	 	$	5,750,000	 	 	 	25	%	 	 	0	%
	 	120	%	 	$	6,000,000	 	 	 	25	%	 	 	0	%
	 	125	%	 	$	6,250,000	 	 	 	25	%	 	 	0	%

 

FY2022

 

	%
    Gross Revenue Target	 	 	$
    Gross Revenue Target	 	 	%
    Increase to Base Salary	 	 	Cash
    Bonus 
(% of New Base Salary)	 
	 	100	%	 	$	10,000,000	 	 	 	15	%	 	 	25	%
	 	105	%	 	$	10,500,000	 	 	 	15	%	 	 	30	%
	 	110	%	 	$	11,000,000	 	 	 	15	%	 	 	35	%
	 	115	%	 	$	11,500,000	 	 	 	15	%	 	 	40	%
	 	120	%	 	$	12,000,000	 	 	 	15	%	 	 	45	%
	 	125	%	 	$	12,500,000	 	 	 	15	%	 	 	50	%

 

FY2023

 

	%
    Gross Revenue Target	 	 	$
    Gross Revenue Target	 	 	%
    Increase to Base Salary	 	 	Cash
    Bonus 
(% of New Base Salary)	 
	 	100	%	 	$	20,000,000	 	 	 	15	%	 	 	25	%
	 	105	%	 	$	21,000,000	 	 	 	15	%	 	 	30	%
	 	110	%	 	$	22,000,000	 	 	 	15	%	 	 	35	%
	 	115	%	 	$	23,000,000	 	 	 	15	%	 	 	40	%
	 	120	%	 	$	24,000,000	 	 	 	15	%	 	 	45	%
	 	125	%	 	$	25,000,000	 	 	 	15	%	 	 	50	%

 

Note:
In the event the Executive is terminated in accordance with clause 22.1 or 22.2, notwithstanding such termination, if Targets are ultimately
met for the financial year during which the termination occurred, the Executive shall be entitled to receive a Cash Bonus that is prorated
for the number of days the Executive was employed during that financial year.

 

    	15

     

    

 

Schedule
2 - Duties and Position Description - includes Key Performance Indicators

 

PURPOSE
OF THE POSITION:

 

	●	Responsible for leading
    the development and execution of the Company’s long-term strategy with a view to creating shareholder value.
	●	The CEO’s leadership role also entails being ultimately responsible for all day-to-day management decisions
and for implementing the Company’s long- and short-term plans.

	●	The CEO acts as a direct liaison between the Board and management of the Company and communicates to the Board on
behalf of management.
	●	The CEO also communicates on behalf of the Company to shareholders, employees, Government authorities, other stakeholders
and the public.

 

POSITION
SPECIFIC REQUIREMENTS:

 

	●	Lead,
    in conjunction with the Board, the development of the Company’s strategy;
	●	Lead
    and oversee the implementation of the Company’s long- and short-term plans in accordance with its strategy;
	●	Ensure
    the Company is appropriately organised and staffed and to have the authority to hire and terminate staff as necessary to enable it
    to achieve the approved strategy;
	●	Ensure
    that expenditures of the Company are within the authorised annual budget of the Company;
	●	Identify
    merger and acquisition opportunities and direct implementation activities;
	●	Assess
    the principle risks of the Company and to ensure that these risks are being monitored and managed;
	●	Ensure
    effective internal controls and management information systems are in place;
	●	Ensure
    that the Company has appropriate systems to enable it to conduct its activities both lawfully and ethically;
	●	Ensure
    that the Company maintains high standards of corporate citizenship and social responsibility wherever it does business;
	●	Act
    as a liaison between management and the Board;
	●	Communicate
    effectively with shareholders, employees, Government authorities, other stakeholders and the public;
	●	Keep
    abreast of all material undertakings and activities of the Company and all material external factors affecting the Company and to
    ensure that processes and systems are in place to ensure that the CEO and management of the Company are adequately informed;
	●	Ensure
    that the Directors are properly informed and that sufficient information is provided to the Board to enable the Directors to form
    appropriate judgments;
	●	Ensure
    the integrity of all public disclosure by the Company;
	●	In
    concert with the Chair, to develop Board agendas; and
	●	To
    abide by specific internally established control systems and authorities, to lead by personal example and encourage all employees
    to conduct their activities in accordance with all applicable laws and the Company’s standards and policies.

 

    	16

     

    

 

Executed
by the parties as an agreement.

 

	Signed
    on behalf and with the authority of 

    Moboom Limited (ACN 136 737 767)	 	 	 
	 	 	 	 
	Melvin Tan	 	 	 
	Name
                                            of Authorised Company Signatory

    
	 	 	Signature
	 	 	 	 
	CFO	 	 	 
	Office
    (Director, Secretary) or Position	 	 	 

 

	Signed
                                            by Gavin Burnett

                                            

     
	 	 	 

     

	 	Signature

 

	In
    the presence of:	 
	 	 
	Witness
    Signature:	 
	 	 
	Witness
    Name:	 
	 	 
	Witness
    Address:	 

 

    	17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]